• Home
  • Search Results
  • Targeting OGG1 arrests cancer cell proliferation by inducing replication stress.

Targeting OGG1 arrests cancer cell proliferation by inducing replication stress.

Nucleic acids research (2020-11-20)
Torkild Visnes, Carlos Benítez-Buelga, Armando Cázares-Körner, Kumar Sanjiv, Bishoy M F Hanna, Oliver Mortusewicz, Varshni Rajagopal, Julian J Albers, Daniel W Hagey, Tove Bekkhus, Saeed Eshtad, Juan Miguel Baquero, Geoffrey Masuyer, Olov Wallner, Sarah Müller, Therese Pham, Camilla Göktürk, Azita Rasti, Sharda Suman, Raúl Torres-Ruiz, Antonio Sarno, Elisée Wiita, Evert J Homan, Stella Karsten, Karthick Marimuthu, Maurice Michel, Tobias Koolmeister, Martin Scobie, Olga Loseva, Ingrid Almlöf, Judith Edda Unterlass, Aleksandra Pettke, Johan Boström, Monica Pandey, Helge Gad, Patrick Herr, Ann-Sofie Jemth, Samir El Andaloussi, Christina Kalderén, Sandra Rodriguez-Perales, Javier Benítez, Hans E Krokan, Mikael Altun, Pål Stenmark, Ulrika Warpman Berglund, Thomas Helleday

Altered oncogene expression in cancer cells causes loss of redox homeostasis resulting in oxidative DNA damage, e.g. 8-oxoguanine (8-oxoG), repaired by base excision repair (BER). PARP1 coordinates BER and relies on the upstream 8-oxoguanine-DNA glycosylase (OGG1) to recognise and excise 8-oxoG. Here we hypothesize that OGG1 may represent an attractive target to exploit reactive oxygen species (ROS) elevation in cancer. Although OGG1 depletion is well tolerated in non-transformed cells, we report here that OGG1 depletion obstructs A3 T-cell lymphoblastic acute leukemia growth in vitro and in vivo, validating OGG1 as a potential anti-cancer target. In line with this hypothesis, we show that OGG1 inhibitors (OGG1i) target a wide range of cancer cells, with a favourable therapeutic index compared to non-transformed cells. Mechanistically, OGG1i and shRNA depletion cause S-phase DNA damage, replication stress and proliferation arrest or cell death, representing a novel mechanistic approach to target cancer. This study adds OGG1 to the list of BER factors, e.g. PARP1, as potential targets for cancer treatment.

Product Number
Product Description

DAPI, for nucleic acid staining
Phytohemagglutinin-L (PHA-L), from Phaseolus vulgaris
Human Serum, Heat Inactivated (from male AB clotted whole blood), USA origin, sterile-filtered
Resazurin sodium salt, powder, BioReagent, suitable for cell culture
cOmplete Protease Inhibitor Cocktail, Tablets provided in EASYpacks
Anti-phospho-Histone H2A.X (Ser139) Antibody, clone JBW301, clone JBW301, Upstate®, from mouse